Aldeyra Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 18.22. In total, the insiders bought 7 777 301 and sold 3 254 341 ALDX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
18.22
Buy 7 777 301 Shares
Sell 3 254 341 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 04, 2024 Stock Option (Right to Buy) Buy Douglas Richard 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Douglas Richard 10 418
Jun 04, 2024 Stock Option (Right to Buy) Buy Douglas Richard 1 215
Jun 04, 2024 Stock Option (Right to Buy) Buy Joyce Martin Joseph 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Joyce Martin Joseph 5 209
Jun 04, 2024 Stock Option (Right to Buy) Buy Joyce Martin Joseph 1 215
Jun 04, 2024 Stock Option (Right to Buy) Buy Walker Neal 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Walker Neal 1 736
Jun 04, 2024 Stock Option (Right to Buy) Buy Miller-rich Nancy 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Miller-rich Nancy 1 736
Jun 04, 2024 Stock Option (Right to Buy) Buy Bronstein Ben 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Bronstein Ben 2 778
Jun 04, 2024 Stock Option (Right to Buy) Buy Bronstein Ben 2 604
Jun 04, 2024 Stock Option (Right to Buy) Buy Phillips Gary M. 40 282
Jun 04, 2024 Stock Option (Right to Buy) Buy Phillips Gary M. 3 473
Jun 04, 2024 Stock Option (Right to Buy) Buy Phillips Gary M. 2 604
Apr 05, 2024 Common Stock Buy Perceptive Advisors Llc 37 712
Apr 04, 2024 Common Stock Buy Perceptive Advisors Llc 140 281
Apr 03, 2024 Common Stock Buy Perceptive Advisors Llc 309 847
Apr 02, 2024 Common Stock Buy Perceptive Advisors Llc 186 051
Apr 01, 2024 Common Stock Buy Perceptive Advisors Llc 8 374
Mar 12, 2024 Common Stock Sell Machatha Stephen 11 537
Mar 12, 2024 Common Stock Sell Machatha Stephen 11 537
Mar 12, 2024 Common Stock Sell Brady Todd C 85 324
Mar 11, 2024 Common Stock Sell Greenberg Bruce 13 201
Click to get the best stock tips daily for free!

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria... ALDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT